Kornimate/medical-research-clean huggingface dataset:
the minimum effective dose (ed90) of liposomal bupivacaine for preserving motor function

Conditions: Motion Sickness

Summary: explore the minimum effective dose of liposomal bupivacaine for preserving motor function

our research group plans to conduct a dose exploration experiment, using a biased coin design sequential method to explore the 90% minimum effective dose of bupivacaine liposomes for preserving motor function after intermuscular groove brachial plexus block surgery in shoulder arthroscopy.

Eligibility criteria:
inclusion criteria: age 41-65 years asa physical condition 1-3 bmi 18-30 kg/m2 undergoing arthroscopic shoulder surgery exclusion criteria: inability to consent to the study pregnancy allergy to local anesthetics preexisting neuropathy cervical pathologies (i.e., herniated disc, myelopathy) chronic pain syndromes (defined as reflex sympathetic dystrophy or complex regional pain syndrome) severe respiratory conditions psychiatric or cognitive disorders that prohibit patients from adhering to the study protocol history of drug or alcohol abuse chronic opioid use (longer than 3 months or daily morphine equivalents more than 5mg/day for 1 month) contraindication for general anesthesia and/or interscalene nerve block and planned open shoulder arthrotomies muscle related diseases

Keywords: shoulder surgery intermuscular sulcus brachial plexus block bupivacaine liposome effective dose
real-world study of ceftazidime avibactam in china

Conditions: Hospital Acquired Pneumonia; Ventilator Acquired Pneumonia; Complicated Intra Abdominal Infections

Summary: this observational study will enroll approximately 450 in patients. patients treated with caz avi for at least 1 dose at around 20 research centers in china will be enroll.

the recruitment will last for approximately 6 months or until recruitment target is met, and information about treatment will be collected from the patients' medical records. patients will be followed from caz avi initiation until death, withdraw of the study, 60 days after discharged from the hospitalization, whichever comes first. the endpoint events will be evaluated at: 7 days, 14 days, 21 days, 30 days, 60 days, and end of treatment (eot) after caz avi initiation, if patients are not discharged prior to the next upcoming timepoint; and 30 days, 60 days after discharge.

Eligibility criteria:
inclusion criteria： * initiate ≥1 dose of ceftazidime-avibactam during hospitalization. * aged ≥ 18 years old at the time of the informed consent signature. * provide signed informed consent. exclusion criteria： * are enrolled in any clinical trial, including enrollment in non interventional studies. * pregnant women.

Keywords: hospital acquired pneumonia ventilator acquired pneumonia complicated intra abdominal infections ceftazidime avibactam carbapenem-resistant enterobacteriaceae
primary hpv self-collection in indonesia

Conditions: Cervical Cancers; CIN - Cervical Intraepithelial Neoplasia; Human Papillomavirus (HPV)

Summary: the purpose of this study is to implement human papillomavirus (hpv) self-collection in indonesia.

after participants give informed consent, they will receive a short educational session about cervical cancer and hpv, after which they will be offered the opportunity to undergo primary hr-hpv testing via self-collection. participants will be contacted within 4 weeks with their results. those who test positive for high-risk hpv will receive a follow-up appointment, at which time visual assessment with acetic acid and/or colposcopy will be performed. those with detectable lesions and/or hpv 16/18+ will undergo treatment with thermal ablation. if they are ineligible for thermal ablation, they will undergo cervical biopsy, endocervical curettage, and/or loop electrosurgical excision procedure (leep) as indicated. anyone with suspicion for cancer will undergo biopsies and referral to a gynecologic oncologist.

Eligibility criteria:
inclusion criteria: * age 30-69 years old * have not had a pap test within the last 3 years or an hpv test within the last 5 years * have never been diagnosed with cervical cancer or high-grade dysplasia * have no history of hysterectomy with cervical removal * expressed willingness to participate in the study, including conducting hpv self-collection, follow-up treatment, and related surveys * speak indonesian or english exclusion criteria: * being pregnant or within 6 weeks postpartum * women who have never engaged in sexual activity * medical, psychiatric, or other conditions that may interfere with compliance with protocols, security assessments, and/or ability/competence to give informed consent * adults who do not have the capacity to give consent may be excluded, as participants must be able to perform activities required by the protocol

Keywords: human papilomavirus (hpv) cervical cancer cervical dysplasia hpv self-collection hpv self-sampling primary hpv test
effect of epstein-barr virus on macrophage m2/m1 migration and epha2 expression in adverse drug reactions

Conditions: Adverse Drug Reactions

Summary: this study aims to investigate the effect of ebv reactivation or ebv reactivation added with dexamethasone(dxm) in patients with adverse drug reactions(cdr) , through evaluating the levels on monocyte, macrophage m2/m1 and cytokines. to investigate whether expression of ebv receptors epha2 could specifically influence on ebv activation in cdrs. we performed a prospective longitudinal study on the frequencies of monocyte, macrophage, m2/m1 and cytokines included il-4,il-13,tnf-α,ifn-γ,ifn-β, cxcl9 and cxcl10 after onset of mpe ,sjs/ten and control groups. pbmcs collected from peripheral blood were cocultured with ebv or ebv with dxm. we next examined whether ebv or ebv with dxm could have a strong impact on the mos, mac, m2/m1 and cytokines and which cytokines could be crucial for the interaction between m2/m1 and ebv, by in vitro cocultures. finally, epha2 were detected to evaluate reactivation of ebv.


Eligibility criteria:
inclusion criteria: 1. age and gender: the study includes male and female patients aged 18 years and older. 2. a.erythema multiforme (mpe) patients: diagnosed based on clinical presentation and medical examination findings.b.stevens-johnson syndrome/toxic epidermal necrolysis (sjs/ten) patients: diagnosed according to the criteria set by the international dermatology society for sjs or ten.c.control group: healthy volunteers, without any history of chronic disease or acute infection, and not currently on any medications. exclusion criteria: 1. other chronic diseases: patients with active heart, liver, kidney disease, or other systemic conditions. 2. acute infection: patients who have had a viral or bacterial infection within the month prior to enrollment. 3. immune status: patients who are immunocompromised or are receiving immunosuppressive therapy. 4. allergy history: patients with a known allergy to any drugs or agents used in the study. 5. pregnancy or lactation: women who are currently pregnant or breastfeeding.
radiation dose escalation in esophageal cancer

Conditions: Esophageal Cancer

Summary: the aim of this trial is to find the maximum tolerable dose of radiation that can be delivered combined with chemotherapy (ddp \& paclitaxel) in patients with inoperable or medically unresectable esophageal cancer.

the rtog 8501 has established concurrent radiochemotherapy as the standard of care for cancer of the esophagus.however, locoregional remain problematic, with 25% of patients having persistence and 20% relapse of locoregional disease following the combined modality approach. new regimen is urgently needed for improving localregional control and survival.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed primary squamous cell carcinoma of the esophagus 2. age 1 8-75. 3. patients must be deemed unresectable disease or patient is not deemed operable due to medical reasons. 4. patients with distant metastasis and life expectancy \>/= 3 months are eligible. 5. zubrod performance status 0 to 2 6. no prior radiation to the thorax that would overlap with the current treatment field. 7. patients with nodal involvement are eligible 8. adequate bone marrow, renal and hepatic functions as assessed by the following: hemoglobin \>/= 10.0 g/dl, platelet count \>/= 1 00,000/mm\^3,absolute granulocyte count (agc) ≥2 × 10\^9 cells/l,bilirubin and aspartate transaminase ≤1.5 ×upper limit of normal (uln), creatinine \</=1 .5 times uln. 9. a signed informed consent must be obtained prior to therapy. 1 0. induction chemotherapy is allowed. exclusion criteria: 1. the presence of a fistula. 2. prior radiotherapy that would overlap the radiation fields. 3. gastroesophageal junction cancer. 4. uncontrolled concurrent illness including, but not limited to: chronic obstructive pulmonary disease(copd) exacerbation or other respiratory illness, serious uncontrolled infection, symptomatic congestive heart failure (chf),unstable angina pectoris, uncontrolled hypertension,or psychiatric illness/social situations that would limit compliance with the study requirements. 5. known hypersensitivity to paclitaxel. 6. any other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study. 7. acquired immune deficiency syndrome. 8. conditions precluding medical follow-up and protocol compliance
pathophysiology of neuronal oscillations within subthalamo-cortical loops in parkinson's disease

Conditions: Parkinson's Disease; Pathophysiology of Neuronal Oscillations Within Subthalamo-cortical Loops

Summary: neuronal activity in circuits between the basal ganglia (bg) and motor cortical areas is abnormally synchronised and rhythmic. the oscillatory activity prevails at 8-30 hz in untreated parkinson's disease (pd) and its amplitude at both subthalamic and cortical levels inversely correlates with motor impairment. moreover, these different levels in bg-cortical loops are coherent in this frequency band. the 8-30 hz activity is suppressed by treatment following treatment with dopaminergic drugs and is partially suppressed prior to and during voluntary movements. an unanswered question is how do bg-cortical loops become so prominently engaged in this oscillatory activity? one possible explanation is that the resonance frequencies of the loops fall in the 8-30 hz band in the untreated state, so that oscillations in this band are transmitted particularly well. this hypothesis was confirmed in a previous series of experiments.the aim is to determine whether the resonance frequency within bg-cortical loops is correlated to the bg-cortical coherence frequency (with 20 subjets during 24 months).

methods: record stn-cortex lfp coherence pattern and then stimulate stn (at 0, 5, 10, 15, 20, 25, 30 hz) in newly implanted patients at rest and during simple and complex motor tasks while recording the steady state evoked potential over the cortex using eeg. the resonance frequency will be calculated as previously (eusebio et al, brain 2009). experiments will be carried out both in the off medication and on medication condition.

Eligibility criteria:
inclusion criteria: * parkinson's disease idiopathique evolving for more than 5 years * dopa-sensibility superior to 50 % * electrodes of stimulation implanted in 2 nst at timone (pr peragut) exclusion criteria: * bad tolerance of the condition off dopa and\\or off stimulation

Keywords: pathophysiology parkinson neuronal oscillations
changes in esophageal distensibility with proton pump inhibitors in patients with esophageal eosinophilia: a pilot study

Conditions: Eosinophilic Esophagitis

Summary: this pilot study will explore whether treatment of eosinophilic inflammation in the esophagus is associated with an improved distensibility of the esophagus. furthermore, previous studies of the esophagus using endoflip only measured distensibility of the distal esophagus, specifically the distal esophagus and esophagogastric junction. eosinophilia in eoe has been demonstrated to affect both upper, middle and lower esophagus. the aim is to measure distensibility both proximal and distal, before and after treatment.


Eligibility criteria:
inclusion criteria: 1. presence of eosinophilia on esophageal biopsy, defined as a peak count of \> 15 eosinophils per high power field (hpf) on light microscopy based on biopsies from at least 2 of the 3 biopsy segments (upper, middle and distal esophagus) exclusion criteria: 1. secondary causes of esophageal eosinophilia has been excluded, such as eosinophilic gi diseases, celiac disease, crohn's disease, esophageal infection, hypereosinophilic syndrome, drug hypersensitivity, vasculitis, pemphigus, connective tissue diseases, graft vs. host disease 2. age \ 65 years 3. contraindication for biopsy, such as presence of esophageal varices, coagulopathy 4. history of esophageal surgery, gastric or esophageal malignancy, anatomical abnormality, or major primary motility disorder (such as achalasia) 5. pregnancy 6. prisoners

Keywords: endoflip
reclaim deep brain stimulation clinical study for treatment-resistant depression

Conditions: Depression

Summary: medtronic, inc. sponsored an investigational study of the reclaim™ deep brain stimulation (dbs) system in people that have treatment-resistant depression. depression is a mood disorder and a serious medical condition that affects millions of americans. depressive symptoms may include loss of interest in things typically enjoyed; decreased energy levels; difficulty concentrating or making decisions; restlessness; and feelings of pessimism, hopelessness, and worthlessness. treatment-resistant depression is a chronic and severe form of depression characterized by failure to respond to traditional forms of treatment, such as antidepressant medications and electroconvulsive therapy. treatment-resistant depression significantly impacts quality of life, productivity, and is a major contributor of disability world-wide. this randomized, double-blind, sham stimulation-controlled, multi-center, prospective, parallel design study used deep brain stimulation technology to test whether active bilateral stimulation can safely and effectively improve depressive symptoms in patients with treatment-resistant depression compared to sham stimulation. participants meeting criteria for the study were implanted with the reclaim dbs system. participants in the active group, who received active stimulation, were compared to the control group, who received sham stimulation, during the 16-week blinded-treatment phase. all participants were monitored for changes in depressive symptoms. after the blinded-treatment phase, all participants received active stimulation. candidates for the trial were adults who had major depressive disorder and had not responded to several treatments for depression. participants in the study continued to receive their current antidepressant medications while participating in the trial.


Eligibility criteria:
inclusion criteria: * consent to participate in screening and study procedures by signing and dating the informed consent form * are diagnosed with major depressive disorder (mdd) * have tried at least 4 different treatments, for example antidepressant medications, combinations of antidepressant medications, and/or electroconvulsive therapy (ect) * screening madrs score ≥ 28 * have had the current major depressive episode persist for at least 2 years * females, if of child-bearing potential, must be using an acceptable method of birth control exclusion criteria: * females: currently pregnant * currently enrolled in or plan to enroll in any concurrent drug and/or device study that may confound the results of this study * have a neurological condition that may jeopardize the safety or the conduct of the study * have any medical conditions unsuitable for undergoing dbs surgery

Keywords: treatment resistant depression treatment refractory depression deep brain stimulation depression
comparison between single shot ultrasonographic guided fascia iliaca block and quadratus lumborum block in hip arthralgia. comparative double blind study

Conditions: Analgesia

Summary: hip arthralgia is a painful condition specially geriatric patients. trail to alleviate pain using locoregional procedures

hip arthralgia is a common presentation in many conditions as rheumatoid arthritis, systemic lupus . pain is agonizing and disabling patinet to have normal life. we are considering fascial plane block versus quadratus lumborum block to dampen pain score.

Eligibility criteria:
inclusion criteria: * all candidates with hip arthalgia (primary or secondery) exclusion criteria: * history of warfarin or clopidogrel adminstration . * patient on chemotherapy * cognitive disrder
a study to compare mabthera (rituximab), fludarabine and cyclophosphamide to mabthera and chlorambucil in participants with chronic lymphocytic leukemia and unfavorable somatic status

Conditions: Lymphocytic Leukemia, Chronic

Summary: this multi-center, randomized study compared the efficacy and safety of mabthera (rituximab) in combination with either fludarabine and cyclophosphamide or with chlorambucil in participants with previously untreated b-cell chronic lymphocytic leukemia and unfavorable somatic status. participants were randomized to receive mabthera (375 mg/m2 intravenously \[iv\] day 1 of cycle 1, 500 mg/m2 iv day 1 cycles 2-6) with either fludarabine (20 mg/m2 iv or 32 mg/m2 orally days 1-3) and cyclophosphamide (150 mg/m2 iv or orally days 1-3) or with chlorambucil (10 mg/m2 orally days 1-7) for 6 cycles of 28 days. anticipated time on study treatment was 24 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, 60-70 or \>70 years of age * cumulative illness rating scale (cirs) comorbidity score \>/=7 if patient is 60-70 years old * previously untreated b-cell chronic lymphocytic leukemia * binet stage b, c or a with progression * ecog performance status 0-2 exclusion criteria: * small-cell lymphoma * autoimmune hemolytic anemia * concomitant malignant disease during enrollment, except for basal cell carcinoma of the skin * chemotherapy for concomitant malignant disease within 12 months prior to study enrollment * richter's syndrome
phase 2 study of telintra® in deletion 5q myelodysplastic syndrome

Conditions: Myelodysplastic Syndrome (MDS)

Summary: study tlk199.2107 is a multicenter, single arm, open-label phase 2 study of oral ezatiostat (telintra®) in patients with lenalidomide (revlimid®) refractory or resistant, red blood cell (rbc) transfusion-dependent, low to intermediate-1 ipss risk, del5q myelodysplastic syndrome (mds).

study tlk199.2107 is a multicenter, single arm, open-label phase 2 study of oral ezatiostat (telintra®) in patients with lenalidomide (revlimid®) refractory or resistant, red blood cell (rbc) transfusion-dependent, low to intermediate-1 ipss risk, del5q myelodysplastic syndrome (mds). independence from red blood cell transfusions, improvement in the levels of red blood cells, white blood cells, and platelets, and the response of the bone marrow were evaluated. patients received a starting dose of 2000 mg total daily dose in divided doses (1000 mg orally twice daily for three weeks (21 days) on therapy followed by a one-week (7 days) off therapy rest period in four-week (28 days) treatment cycles. patients continued treatment until documentation of lack of mds response, mds progression, unacceptable toxicity, or patient withdrawal from the study.

Eligibility criteria:
inclusion criteria: * primary or de novo mds * low or intermediate-1 ipss risk mds * deletion of the 5q chromosome \[del(5q) mds\] * refractory or resistant to lenalidomide (revlimid) * ecog performance score of 0 or 1 * documentation of significant anemia with or without additional cytopenia * adequate kidney and liver function * patients must have discontinued hematopoietic growth factors at least 3 weeks prior to study entry exclusion criteria: * prior allogenic bone marrow transplant for mds * known sensitivity to ezatiostat (injection or oral tablets) * prior treatment with hypomethylating agent (hma) (e.g., azacitadine, decitabine) * history of mds ipss risk score of greater than 1.0 * pregnant or lactating women * any severe concurrent disease, infection or comorbidity that, in the judgement of the investigator, would make the patient inappropriate for study entry * oral steroids greater than 10 mg per day. exceptions: those prescribed for other conditions (such as new adrenal failure, asthma, arthritis) or brief steroid use (such as tapered dosing for an acute non-mds condition) * history of hepatitis b or c, or hiv

Keywords: hematology mds myelodysplastic syndrome low risk mds intermediate-1 risk mds int-1 risk mds transfusion dependence lenalidomide refractory revlimid refractory lenalidomide resistant revlimid resistant telintra ezatiostat ezatiostat hydrochloride tlk199 glutathione glutathione analog glutathione transferase glutathione transferase p1-1 inhibitor gst p1-1 inhibitor apoptosis differentiation enzyme inhibitor
rom outcomes in patients undergoing a primary tka

Conditions: Knee Osteoarthritis

Summary: the goal of this prospective, randomized study is to compare the outcomes of patients undergoing primary tka after photographing final knee range of motion immediately post-operatively and sharing these photographs with patients at their first follow-up appointment versus a group that does not see a photograph.

the goal of this prospective, randomized study is to compare the outcomes of patients undergoing primary total knee arthroplasty (tka) after photographing final knee range of motion immediately postoperatively and sharing these photographs with patients at their first follow-up appointment versus a group that does not see a photograph. the knee will be photographed in maximum flexion and extension. the primary objectives will be to compare the range of motion of the operative knee at 2 weeks and 6 weeks postoperatively. in the investigator's institution, patients who have failed to achieve 90 degrees of flexion at a postoperative period of 6 weeks undergo manipulation of the knee under anesthesia (mua). the investigators will also measure how many patients require mua in the photograph group and non-photograph group. mua will be performed if patients fail to achieve 90 degrees of flexion at 6 weeks post-op.

Eligibility criteria:
inclusion criteria: 1. patient is between the age of 22-89 2. patient is scheduled to undergo a unilateral, cementless primary tka, secondary to osteoarthritis 3. patient agrees to participate as a study subject and signs the informed consent and research authorization documents 4. patient is able to read and speak english. exclusion criteria: 1. patient is under the age of 22 or over the age of 89 2. patient has preoperative stiffness/contracture of the knee secondary to post-traumatic arthritis 3. patient is scheduled to undergo a bilateral tka surgery 4. patient is unable to read and speak english